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1. Introduction 
Automatic implantable cardioverter defibrillators (ICDs) have been used widely for the 
prevention of recurrent sudden cardiac death and the treatment of life-threatening 
ventricular tachyarrhythmias in ambulatory patients, since 1980 (Mirowski M et al., 1982). 
The remarkable efficacy of the ICD has been demonstrated to be 95% at 3 years and this has 
led to its ever-increasing use (Linl G et al., 2009).  
Despite this benefit, there are many potential complications associated with ICDs (Pfeiffer D 
et al., 1994; Linl G et al., 2009). Nevertheless, the rate of complications related to the ICDs 
has fallen markedly with the evolution from a large device that required an abdominal 
pocket and insertion of an epicardial lead system via thoracotomy to the current use of 
much smaller transvenous pectoral devices (Krohn J et al., 2001; DiMarco JP et al., 2003). The 
incidence of ICD complications is difficult to determine due to inconsistent definitions and 
the lack of mandatory reporting. Nevertheless, women are more likely than men to have in-
hospital adverse events related to ICD implantation (Peterson PN et al., 2009). 
2. Definitions, aims and search strategy 
The European Community and the International Standards Organization have provided 
standard criteria for adverse events observed during trials with implantable medical 
devices, defining an adverse event as any undesirable clinical occurrence and taking into 
account the severity and relationship to the implanted device. This does not include any 
information regarding the underlying technical or clinical cause (Rosenqvist M et al., 1998). 
Thus, complications are defined as any undesirable clinical occurrence related to the ICD 
implantation and function including intraoperative mortality and 30 day post-operative 
mortality.   
This chapter aims to perform a systematic review of the published literature to provide the 
reader with the best available evidence and most current medical knowledge regarding 
pulmonary, cardiovascular and mechanical complications that occur due to the implantation 
of ICDs. Moreover, this chapter will attempt to ameliorate the weaknesses inherent in the 
current medical literature and scientific published medical literature regarding the issue. 
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Therefore, English language and adult population published literature from 1980 to 
December 2010 was searched using PubMed, Current Contents, Cochrane Library, Embase, 
Cinahl, Google Scholar and supplemented by a manual review of bibliographies of all 
relevant papers. Proceedings from relevant conferences, reference lists, relevant clinical 
trials and research registers were also searched. English language published literature from 
1980 to 2010 was sought utilizing the following search strategy: implantable cardioverter 
defibrillators [MeSH] and/or pulmonary and/or cardiac and/or mechanical/ device-related 
complications. Studies were required to present sole evidence justifying the presence of 
complications secondary to the ICD. Data from each study was extracted by one author and 
reviewed by the two others. 
3. Pulmonary complications 
The majority of pulmonary complications were associated with the placement technique of 
the ICDs (Kuck KH et al., 2000). Implantation of an ICD involves placement of both the ICD 
lead system and the pulse generator. Current ICD lead systems are typically placed 
transvenously via the axillary, subclavian, or cephalic vein. This approach has largely 
replaced the surgical epicardial lead placement of the ICD which was associated with 
considerable postoperative morbidity (Chevalier P et al., 1996; Kuck KH et al., 2000) and 
with pulmonary complications that are unique to thoracotomy such as atelectasis with 
pneumonia, symptomatic pleural effusions, ARDS (adult respiratory distress syndrome).  
In 1985, Lurie AL et al reported complications in a series of 22 patients that underwent ICD 
placement by thoracotomy. Among them, 77% presented with atelectasis, infiltrates or 
pleural effusion in the chest radiograph and 13% with pneumothoraces resulting from 
transvenous lead placement. The authors (Lurie AL et al., 1985) reported these as transient 
postimplantation complications. Pneumothorax, infections, and bleeding tend to occur soon 
after implant (Krohn J et al., 2001; Krohn J et al., 2003). As subclavian vein puncture may be 
associated with pneumothorax in approximately 1% of patients, the cephalic vein should be 
preferred for nonthoracotomy lead placement (Krohn J et al., 2003).  
Pneumothorax occurs uncommonly and is directly related to operator experience, the 
difficulty of the subclavian puncture, and is almost eliminated using the cephalic cut-down 
technique. However, these traditional comparisons may become obsolete as the axillary vein 
cannulation technique (Martin C et al. 1996) threatens to eliminate this controversy. Often 
the pneumothorax is asymptomatic and noted in routine follow up plain chest radiograph.  
Recurrent hemoptysis has been reported as a delayed complication on the grounds of ICD 
placement (Kao N et al., 1991; Verheyden CN et al., 1994; Dasgupta A et al., 1998; Driscoll JA 
et al., 2005). Clinicians caring for patients with an ICD should be aware of this complication 
and consider patch erosion into the bronchus as a cause, albeit rare, in the differential 
diagnosis of recurrent hemoptysis. Rarely, the patch erosion can be visualised 
bronchoscopically as the underlying cause of hemoptysis (Dasgupta A et al., 1998). 
Common radiographical findings can be a pleural infusion and vague infiltrates (Dasgupta 
A et al., 1998). Patch removal may reveal destruction of a significant part of the underlying 
bronchus, thereby prohibiting bronchial reconstruction. In patients who have undergone 
placement of an automatic ICD using pericardial or epicardial defibrillator patches and 
present with hemoptysis, bronchopericardial fistula should be also suspected (Nolan RL et 
al., 1999). Air between a defibrillator patch and the heart on chest radiographs or CT is 
diagnostic. 
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Infections of the ICD electrodes causing recurrent pneumonias are common and could lead 
to ARDS if remain uncontrolled. In reported cases, the ICD electrodes grew Methicillin 
sensitive Staphylococcus epidermidis/aureus, Methycillin Resistant Staphylococcus aureus, 
Haemophillus Paranfluenzae, Aspergillus fumigatus, Pseudomonas aeruginosa, while clots on the 
ICD patch grew Haemophillus Influenzae (Dasgupta A et al., 1998; Cook RJ et al., 2004; Pai RK 
et al., 2004; Ioannides MA et al., 2006; Rusanov A, Spotnitz HM. 2010); these pathogens are 
quite commonly isolated in infections caused by ICD placement. Infection of the patch can 
ultimately lead to its dislodgement and migration to the lung. Regarding the culture 
findings, it is difficult to be sure whether there was primary device infection with the 
pathogens presumably introduced during the ICD placement, a primary pneumonia with 
subsequent seeding of the ICD patch, or an underlying hematoma formation at the time of 
patch placement which then secondarily became infected, leading to subsequent erosion and 
pulmonary complications. Concomitantly, infections have increased the frequency of lead 
extraction. The frequency of lead infections has also risen faster than expected based solely 
on the number of implanted leads (Voigt A et al., 2006) 
Patients developing severe pneumonias could also present with septic pulmonary embolism 
secondary to the infection(Cook RJ et al., 2004). This typically produces abnormalities on 
chest radiography, but its appearance is not uniform (Ryu JH et al., 2003; Huang RM et al., 
1989; Rossi SE et al.,2000); multiple bilateral cavitary nodules at the lung periphery are most 
typical (Wong KS et al., 2002). Characteristic CT findings are discrete nodules in various 
stages of cavitation with visible feeding vessels (Rossi SE et al., 2000). However, multifocal 
cavitary lesions in the lung can also be associated with neoplasms, pulmonary infarctions, 
abscesses, vasculitides, congenital abnormalities, rheumatoid nodules, and pneumoconioses 
(Ryu JH et al., 2003). Consequently, correlation with the clinical context is important to 
narrow the broad differential diagnosis.  
However, in this context, in 1997 Lick SD et al considered a cavitary lesion in a patient 
bearing an ICD and presenting with cough, malaise and weight loss commonly suspicious 
for a cavitary malignant neoplasm. Fiberoptic bronchoscopy was performed and no 
evidence of a malignant tumour was seen. Surprisingly, a defect was found in the lingular 
bronchus through which the bronchoscope could pass, opening into a large air-filled cavity, 
in part bordered by the patch itself. Cultures from the cavity debris grew Aspergillus and 
Staphylococcus aureus. 
Hemothorax has also been reported as a late pulmonary complication of an ICD placement 
usually after the onset of pleuritic pain (Kremmers MS et al., 1995; Quigley RL et al., 1996). 
This complication results from trauma to the great vessels rather than the lung. The risk can 
be minimised by direct inward and outward passes of the puncture needle rather than a 
side-to-side potentially lacerating movement (Pavia S, Wilkoff B. 2001). 
Air embolism has been reported during deep inspiration at the time of central venous access 
causing significant air to be drawn into the venous system due to the physiological negative 
pressure developed (Pavia S, Wilkoff B. 2001). It can be prevented through operator care 
and using introducers with hemostatic valves. The diagnosis is obvious because it is 
heralded by a hissing sound as the air is sucked in and with the fluoroscopic confirmation 
that follows. Patients are surprisingly tolerant of this occurrence. However, respiratory 
distress, hypotension, and arterial oxygen desaturation may occur depending on the size of 
the embolus and 100% oxygen should be administered alone with ionotropic support in 
some cases (Ellenbogen KA, Wood MA. 2005). Aspiration of the embolus from the right 
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heart has also been successful. However, usually no therapy is required, as the air is filtered 
and consequently absorbed by the lungs. 
4. Cardiac complications 
Endocarditis secondary to leads’ infection is one of the most common cardiac complications 
of ICDs. The majority of infections are caused by coagulase negative Staphylococcus and 
Staphylococcus aureus and rarely Staphylococcus lugdunensis (Anguera et al 2005; Liu PY et al., 
2010; Chopra A et al., 2010). Although the risk of infection of intracardiac devices is well 
known, the clinical presentation of this complication can be insidious, delayed in onset and 
difficult to diagnose. The onset of symptoms can be in the first 6 months (Cacoub P et al., 
1998) or in the first few years. Right sided endocarditis on the grounds of Aspergillus 
fumigatus infection has been reported (Cook RJ et al., 2004) as a delayed complication. The 
infection presented as persistent pulmonary infiltrates and anemia more than 2 years after 
the implantation of the device. Endocarditis caused by Staphylococcus capitis has also been 
reported and presented with a subacute course (Cone LA et al., 2005). Infrequently, gram 
negative bacilli can also cause lead infection and endocarditis. Klebsiella pneumoniae is a 
pathogenic gram negative bacillus which has been reported to cause ICD associated 
endocarditis (Pai RK et al., 2006). 
Acute pericardial effusion and tamponade can occur secondary to lead perforation of the 
heart. This is an infrequent complication of device implantation which may also present as a 
subacute process days later, or even as a delayed process (Mahapatra S et al., 2005; Khan 
MN et al., 2005; Henrikson CA et al., 2006). 
Some series have suggested an increase in ventricular arrhythmias after the implantation of 
epicardial patch electrodes (Bocker D et al., 1993). However, one study which randomized 
900 patients undergoing coronary artery bypass grafting to an ICD or no ICD found no 
difference in the incidence of postoperative ventricular or supraventricular arrhythmias 
between the two groups (Curtis AB et al., 1998). 
Many patients who receive an ICD have left ventricular dysfunction. An unresolved 
question is whether worsening myocardial function would affect the defibrillation 
threshold. In an animal model, the development of congestive heart failure did not alter 
defibrillation energy requirements (Friedman PA et al., 1998 ). 
Multiple low energy defibrillation shocks via an endocardial right ventricular electrode 
cause significant myocardial damage in dogs, manifested as mitochondrial injury and 
dysfunction (Schirmer U et al., 1997). Although these changes are more apparent in the right 
ventricle, they are also seen in the left ventricle. 
Myocardial necrosis is another cardiac ICD complication. Rapid consecutive shocks from the 
ICD results in elevation in serum troponin I, reflecting subtle injury to the heart. In one series 
of 12 patients who received a mean of 6 shocks with a mean cumulative energy of 112 J during 
ICD implantation, 5 had elevated troponin I levels which peaked within the first 12 hours after 
the shocks and were normal or near normal by 24 hours (Joglar JA et al., 1999). Only 1 of these 
patients had an increase in CK-MB and no patient had associated ECG changes. 
5. Mechanical complications 
Mechanical complications can be divided into lead/device/pocket related and 
inappropriate defibrillator shocks. 
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Lead-related problems occur in approximately 5% of patients, including lead dislodgement, 
fracture, and insulation defects, which can lead to either over- or undersensing. Lead-related 
problems can occur at any time during long-term follow-up (Kron J et al., 2001; Yap SC et 
al., 2007) with the vast majority of lead dislodgments occurring within the first post-
operative months. With increasing age of the transvenous lead systems, a growing number 
of lead fractures and insulation defects have to be expected (Mewis C., 1997; Kron J., 2003). 
Necessity for operative revision is reported for 6% within 1 year of initial implant and up to 
15% during 4 years (Kron J et al., 2001). A relation between the incidence of lead-related 
complications and the number of leads used in ICD systems has been reported (Takahashi T 
et al.,2002). Lead dislodgments occur significantly more frequently in patients with dual 
chamber ICDs (12%) and in patients with biventricular ICDs (19%) when compared with 
single chamber ICDs (3%).  
One study evaluated 171 patients who received an epicardial lead system and were 
followed for 4 years: lead malfunction occurred in 11% of patients and in up to 28% with 
some systems (Brady PA et al., 1998). The majority of lead malfunctions occurred more than 
2 years after implantation; most patients were asymptomatic (58%). Another report 
evaluated 132 patients who received a transvenous lead system and pectoral implantation 
and were followed for 30 months (Mehta D et al., 1998). A 13% incidence of erosion of the 
lead insulation was noted when systems using long transvenous leads and relatively larger 
generators were used. This problem is caused by pressure of the generator against the lead. 
Pocket-related complications including skin erosion, hematoma and seroma, wound 
infection, or device migration usually occur within the first 6 months after implantation 
(Gold MR et al., 1996).  
Device-related complications include migration, skin erosion, and necrosis (due to the size 
and weight of the generator) and premature battery depletion. Fortunately these problems 
are uncommon, occurring in less than 2% of patients. In addition, hematomas or seromas 
can form in the pulse generator pocket.  
Twiddler's syndrome can also be included in the device-related complications, in which 
twisting or rotating the device in its pocket results in lead dislodgement and device 
malfunction, can occur in patients with an ICD. It is most likely to develop when the device 
is implanted in the abdomen of an obese patient who is able to rotate it within the 
abdominal pocket (Boyle NG et al. 1998). Patients most often present with an increase in 
bradycardic pacing threshold or lead impedance; however, there is a possibility that the 
device will fail to sense and treat an arrhythmia. Careful suturing of the device to the fascia 
and matching pocket and device size is important to avoid this complication. 
Defibrillation-related problems represent a serious technical entity. A high defibrillation 
energy requirement (over 24 Joules) provides little margin for safety. However, in the 
absence of any changes in the clinical status of the patient, defibrillation energy 
requirements with a transvenous lead system are generally stable over a three month period 
(Newman D et al., 1997). 
Inappropriate shocks most often occur due to supraventricular tachycardia, self-terminating 
VT, and sensing artifacts, e.g., myopotentials or T wave oversensing. It has been reported that 
inappropriate shocks for supraventricular tachyarrhythmias are more often in younger 
patients and in patients who have nonischemic dilated cardiomyopathy compared to patients 
with coronary artery disease (Alter P et al., 2005; Lin G et al., 2009; Lee DS et al., 2010). 
Potential induction of fatal ventricular fibrillation by inappropriate shocks is known from 
anecdotal reports (Messali A et al., 2004). Use of leads with true bipolar sensing can reduce 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
76
sensing artifacts. The most important precipitating factor is myocardial ischemia, but other 
causes are electrolyte disturbances, and episodes of congestive heart failure resulting in an 
increase in sympathetic tone. However, newer atrial/dual chamber devices can effectively 
detect specific atrial and ventricular arrhythmias and can accurately discriminate between 
atrial tachycardia/atrial flutter and atrial fibrillation (Swerdlow CD et al., 2000). These devices 
can be programmed for mode switching to prevent inappropriate tracking of an atrial 
arrhythmia; to withhold inappropriate ventricular therapy; and to deliver appropriate therapy 
for the atrial tachyarrhythmia, such as pace termination of atrial flutter. Treatment with a 
sufficient dose of β-blockers may help to decrease the number of inappropriate shocks due to 
atrial flutter of fibrillation by slowing the ventricular rate (Pacifico A et al., 1999). In addition, 
prognostic benefits of β-blockers are well known in patients with coronary artery disease as 
well as in patients with heart failure (Packer M et al., 2001). Therefore, all patients with 
coronary heart disease and with non-ischemic dilated cardiomyopathy should receive β-
blockers as standard therapy, unless there is a contraindication. Furthermore, it has been 
found a significantly lower incidence of inappropriate shocks due to supraventricular 
tachyarrhythmias in patients with versus without amiodarone therapy (Alter P et al., 2005). In 
addition, the rate cut-off for detecting ventricular tachyarrhythmias should not be 
programmed too low in order to decrease the overlap with supraventricular tachyarrhythmias. 
Since the latter is not possible in many patients with symptomatic slow ventricular 
tachyarrhythmias, state-of-the-art ICD discrimination algorithms should be used in order to 
distinguish supraventricular arrhythmias from VT.  
Moreover, ICD related shocks to rescuers during CPR have been reported (Clements PA., 
2003, Siniorakis E et al., 2009). In the case presented by Siniorakis E et al., CPR was 
performed in a patient bearing an ICD and presenting cardiac arrest with an initial rhythm 
of pulseless electrical activity. Ten minutes after starting CPR, the rescuer received an 
electric shock. This first shock of 21.9 J affecting the rescuer was triggered by chest 
compression-related muscular noise. This was mistaken by the ICD as ventricular 
fibrillation. In this context, there should be a warning from ICD manufacturers about the 
risks of shocks from ICDs during CPR. 
An increase in the chronic defibrillation threshold may also occur (Martin DT et al., 1995). 
This problem may result from intense fibrosis and the cumulative acute damage produced 
by defibrillation discharges at the ICD electrode-myocardial interface (Epstein AE 1998 et 
al., 1998). However, the increase in defibrillation threshold may not be clinically significant 
with modern devices. In addition, changing the polarity of the leads may result in a 
reduction in the defibrillation threshold (Schauerte P et al., 1997). 
6. Conclusions 
The potential complications of ICDs are significant in terms of diversity and patient 
impact. For this reason, the decision to implant a device should be based on sound 
guidelines with definite expected patient benefit. Although it is a relatively simple 
procedure the potential complications may, at times, be life-threatening. Early recognition 
of these complications is the prerequisite for advances in ICD technology, in management 
strategies to avoid their recurrence and in improved patient quality of life. With a clear 
understanding of the accepted implant indications and possible complications and a 
meticulous approach to the implant and post-implant follow-up, the incidence of 
complications can be minimised.  
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